Cabot Wealth Management’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Cabot Wealth Management’s Portfolio NAVB Stock Details NAVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-3,075	Closed	-$8K	–	138
2019 Q1	$8K	Hold	3,075	–	–	﹤0.01%	129
2018 Q4	$6K	Hold	3,075	–	–	﹤0.01%	128
2018 Q3	$14K	Buy	+3,075	New	+$11.7K	﹤0.01%	125
2015 Q1	–	Sell	-1,500	Closed	-$57K	–	156
2014 Q4	$57K	Buy	1,500 +1,000	+200%	+$27.5K	0.01%	145
2014 Q3	$13K	Hold	500	–	–	﹤0.01%	144
2014 Q2	$15K	Buy	+500	New	+$16.2K	﹤0.01%	143

Other funds holding NAVB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

ACM

Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cabot Wealth Management's NAVB Position: Q2 2019 in Review

Cabot Wealth Management sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q2 2019, closing a stake of 3,075 shares — an estimated $8K sold.

Cabot Wealth Management first reported a position in NAVB in Q2 2014 and held it in 6 quarters. The position peaked at $57K in Q4 2014. 27 funds tracked by Wall St. Rank hold NAVB as of Q2 2019.

Cabot Wealth Management reported no remaining Navidea Biopharmaceuticals Inc. position as of Q2 2019 after selling out during the quarter.
Cabot Wealth Management sold 3,075 Navidea Biopharmaceuticals Inc. shares in Q2 2019, an estimated $8K.
Cabot Wealth Management first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2014 and held it in 6 quarters.
Cabot Wealth Management's Navidea Biopharmaceuticals Inc. position peaked at $57K in Q4 2014.
27 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q2 2019.

Based on Cabot Wealth Management's 13F filing for Q2 2019, filed 6 Aug 2019.